Clinical Trial Update: Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating dose-dense rituximab for high-risk newly diagnosed immune thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: New York Medical College | Conditions: Immune Thrombocytopenic Purpura | Phase 1 | Status: RECRUITING